Novel cbg derivatives can reduce inflammation, pain and obesity

Natalya M. Kogan, Yarden Lavi, Louise M. Topping, Richard O. Williams, Fiona E. McCann, Zhanna Yekhtin, Marc Feldmann, Ruth Gallily, Raphael Mechoulam

פרסום מחקרי: פרסום בכתב עתמאמרביקורת עמיתים

16 ציטוטים ‏(Scopus)

תקציר

Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.

שפה מקוריתאנגלית
מספר המאמר5601
כתב עתMolecules
כרך26
מספר גיליון18
מזהי עצם דיגיטלי (DOIs)
סטטוס פרסוםפורסם - ספט׳ 2021
פורסם באופן חיצוניכן

טביעת אצבע

להלן מוצגים תחומי המחקר של הפרסום 'Novel cbg derivatives can reduce inflammation, pain and obesity'. יחד הם יוצרים טביעת אצבע ייחודית.

פורמט ציטוט ביבליוגרפי